The proposed study aims to build on the results of clinical studies DIUR-003 and DIUR-005 and evaluate the long-term safety of Chronocort® and also its long term efficacy.

Phase 1

Conditions: Congenital adrenal hyperplasia (CAH)
is generally due to 21-hydroxylase deficiency, is a disease of the adrenal cortex characterised by cortisol deficiency with or without aldosterone deficiency, and androgen excess. Subjects with CAH are at risk of developing a number of clinical manifestations, such as obesity in children, insulin resistance, and polycystic ovaries, which may contribute to infertility in women with CAH. Oligomenorrhoea or amenorrhoea may be present in adolescence.
MedDRA version: 20.0Level: LLTClassification code 10010323Term: Congenital adrenal hyperplasiaSystem Organ Class: 100000004850
Therapeutic area: Diseases [C] - Hormonal diseases [C19]

Registration Number: EUCTR2015-005448-32-GB

Lead Sponsor: Diurnal Ltd

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Authorised-recruitment may be ongoing or finished

Sex: All

Target Recruitment: 136

Inclusion Criteria

1. Subjects with congenital adrenal hyperplasia (CAH) who have successfully completed the DIUR-003 or DIUR-005 clinical trials with the current formulation of Chronocort®
2. Provision of signed written informed consent.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 136
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

1. Co-morbid condition requiring daily administration of a medication (or consumption of any material) that interferes with the metabolism of glucocorticoids
2. Clinical or biochemical evidence of hepatic or renal disease. Creatinine over twice the ULN or elevated liver function tests (ALT or AST >2 times the ULN)
3. Subjects on regular daily inhaled, topical, nasal or oral steroids for any indication other than CAH
4. History of malignancy (other than basal cell carcinoma successfully treated >6 months prior to entry into the study)
5. Participation in another clinical trial of an investigational or licensed drug or device within the 3 months prior to inclusion in this study
6. Subjects with a history of bilateral adrenalectomy
7. Subjects unable to comply with the requirements of the protocol.